Indo-Bangla Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Indo-Bangla Pharmaceuticals's earnings have been declining at an average annual rate of -47.5%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been declining at an average rate of 20.4% per year.
Key information
-47.5%
Earnings growth rate
-48.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.0% |
| Revenue growth rate | -20.4% |
| Return on equity | -1.1% |
| Net Margin | -8.5% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Indo-Bangla Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 212 | -18 | 32 | 0 |
| 31 Dec 23 | 296 | -8 | 44 | 0 |
| 30 Sep 23 | 338 | -10 | 65 | 0 |
| 30 Jun 23 | 374 | 8 | 68 | 0 |
| 31 Mar 23 | 375 | -35 | 128 | 0 |
| 31 Dec 22 | 416 | -22 | 124 | 0 |
| 30 Sep 22 | 447 | 7 | 109 | 0 |
| 01 Jul 22 | 485 | 25 | 111 | 0 |
| 31 Mar 22 | 619 | 117 | 92 | 0 |
| 31 Dec 21 | 654 | 118 | 103 | 0 |
| 30 Sep 21 | 731 | 135 | 121 | 0 |
| 01 Jul 21 | 782 | 135 | 140 | 0 |
| 31 Mar 21 | 788 | 105 | 134 | 0 |
| 31 Dec 20 | 843 | 137 | 138 | 0 |
| 30 Sep 20 | 862 | 150 | 135 | 0 |
| 30 Jun 20 | 866 | 156 | 133 | 0 |
| 31 Mar 20 | 853 | 186 | 135 | 0 |
| 31 Dec 19 | 828 | 183 | 132 | 0 |
| 30 Sep 19 | 790 | 170 | 130 | 0 |
| 30 Jun 19 | 741 | 155 | 127 | 0 |
| 31 Mar 19 | 742 | 134 | 115 | 0 |
| 31 Dec 18 | 695 | 117 | 113 | 0 |
| 30 Sep 18 | 667 | 102 | 116 | 0 |
| 30 Jun 18 | 660 | 98 | 115 | 0 |
| 31 Mar 18 | 641 | 89 | 115 | 0 |
| 30 Jun 17 | 617 | 88 | 109 | 0 |
| 31 Mar 17 | 581 | 93 | 101 | 0 |
| 30 Jun 16 | 445 | 59 | 92 | 0 |
| 01 Jul 15 | 435 | 60 | 85 | 0 |
Quality Earnings: IBP is currently unprofitable.
Growing Profit Margin: IBP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IBP is unprofitable, and losses have increased over the past 5 years at a rate of 47.5% per year.
Accelerating Growth: Unable to compare IBP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IBP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.2%).
Return on Equity
High ROE: IBP has a negative Return on Equity (-1.13%), as it is currently unprofitable.